Association of interleukin-10 gene variation with breast cancer prognosis

被引:47
作者
Gerger, Armin [1 ]
Renner, Wilfried [2 ,3 ]
Langsenlehner, Tanja [4 ]
Hofmann, Guenter [1 ]
Knechtel, Gudrun [1 ]
Szkandera, Joanna [1 ]
Samonigg, Hellmut [1 ]
Krippl, Peter [5 ]
Langsenlehner, Uwe [6 ]
机构
[1] Med Univ Graz, Div Oncol, Dept Internal Med, A-8036 Graz, Austria
[2] Med Univ Graz, Inst Clin Med, A-8036 Graz, Austria
[3] Med Univ Graz, Diagnost Lab, A-8036 Graz, Austria
[4] Med Univ Graz, Clin Therapeut Radiol & Oncol, A-8036 Graz, Austria
[5] Reg Hosp Fuerstenfeld, Dept Internal Med, A-8280 Fuerstenfeld, Austria
[6] Steiermaerk Gebietskrankenkasse, Internal Outpatient Dept, A-8011 Graz, Austria
关键词
Breast cancer; Prognosis; Polymorphism; Interleukin; PROMOTER POLYMORPHISM; TUMOR-MARKER; IL-10; METASTASIS;
D O I
10.1007/s10549-009-0417-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Genetic polymorphisms are responsible for inter-individual variation and diversity and have been recently considered as the main genetic elements involved in the development and progression of cancer. We examined associations between common germline genetic variants in 7 genes involved in folate metabolism, cell proliferation and apoptosis, prostaglandin synthesis, detoxification of compounds and inflammation, and disease-free survival among women diagnosed with invasive breast cancer. DNA from up to 432 women was genotyped for 8 polymorphisms. The genotypes of each polymorphism were tested for association with disease-free survival using univariate and multivariate Cox regression analysis. The model was adjusted for known breast cancer prognostic factors. The rare allele of the IL-10 592C > A polymorphism was significantly associated with reduced disease-free survival (P = 0.018, risk ratio of recurrence (RR) = 1.45, 95% confidence interval (CI) = 1.06-1.98), which was not attenuated after adjusting for age at diagnosis, tumor size, lymph node status, clinical stage, histological grade, estrogen receptor status, progesterone receptor status, and treatment modalities (P = 0.019, RR = 1.48, 95% CI = 1.066-2.044). No association was found between MTHFR 677C > T, TGFB1 29T > C, FASLG 844C > T, FAS 1377G > A, FAS 670A > G, PTGS2 8473T > C and SULT1A1 638G > A polymorphisms and disease-free survival. Our data suggest that the rare allele of IL-10 592C > A may be a potential prognostic marker in breast cancer for disease-free survival.
引用
收藏
页码:701 / 705
页数:5
相关论文
共 26 条
[1]
Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review [J].
Balasubramanian, S. P. ;
Azmy, I. A. F. ;
Higham, S. E. ;
Wilson, A. G. ;
Cross, S. S. ;
Cox, A. ;
Brown, N. J. ;
Reed, M. W. .
BMC CANCER, 2006, 6 (1)
[2]
Crawley E, 1999, ARTHRITIS RHEUM-US, V42, P1101, DOI 10.1002/1529-0131(199906)42:6<1101::AID-ANR6>3.0.CO
[3]
2-Y
[4]
FIORENTINO DF, 1991, J IMMUNOL, V147, P3815
[5]
A multigenic approach to predict breast cancer risk [J].
Gerger, Armin ;
Langsenlehner, Uwe ;
Renner, Wilfried ;
Weitzer, Werner ;
Eder, Tanja ;
Yazdani-Biuki, Babak ;
Hofmann, Guenter ;
Samonigg, Hellmut ;
Krippl, Peter .
BREAST CANCER RESEARCH AND TREATMENT, 2007, 104 (02) :159-164
[6]
New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK [J].
Hayes, Daniel F. ;
Ethier, Stephen ;
Lippman, Marc E. .
BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 (02) :237-238
[7]
Prognostic significance of increased IL-10 production in patients prior to allogeneic bone marrow transplantation [J].
Holler, E ;
Roncarolo, MG ;
Hintermeier-Knabe, R ;
Eissner, G ;
Ertl, B ;
Schulz, U ;
Knabe, H ;
Kolb, HJ ;
Andreesen, R ;
Wilmanns, W .
BONE MARROW TRANSPLANTATION, 2000, 25 (03) :237-241
[8]
Interleukin-10 polymorphisms, cancer susceptibility and prognosis [J].
Howell, W. Martin ;
Rose-Zerilli, Matthew J. .
FAMILIAL CANCER, 2006, 5 (02) :143-149
[9]
Hsieh S., 2007, BREAST DIS, V26, P157, DOI DOI 10.3233/BD-2007-26114
[10]
Opinion - Host genetics influence tumour metastasis [J].
Hunter, K .
NATURE REVIEWS CANCER, 2006, 6 (02) :141-146